Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma

Abstract

The objective of the study was to evaluate the effect of neoadjuvant chemotherapy on the survival of patients with oropharyngeal cancer. Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy. The loco-regional treatment consisted either of surgery plus plus radiotherapy or of radiotherapy alone. Three cycles of chemotherapy consisting of Cisplatin (100 mg/m2) on day 1 followed by a 24-hour i.v. infusion of fluorouracil (1000 mg/m2/day) for 5 days were delivered every 21 days. 2-3 weeks after the end of chemotherapy, local treatment was performed. The trial was conducted by the Groupe d'Etude des Tumeurs de la Tête Et du Cou (GETTEC). A total of 318 patients were enrolled in the study between 1986 and 1992. Overall survival was significantly better (P = 0.03) in the neoadjuvant chemotherapy group than in the control group, with a median survival of 5.1 years versus 3.3 years in the no chemotherapy group. The effect of neoadjuvant chemotherapy on event-free survival was smaller and of borderline significance (P = 0.11). Stratification of the results on the type of local treatment, surgery plus radiotherapy or radiotherapy alone, did not reveal any heterogeneity in the effect of chemotherapy.

References 5

1. 1.

   Calais G., Garand G., Beutter P., Le Floch O. Carcinomes avancés de l'oropharynx: valeur d'une chimiothérapie d'induction précédant le traitement locorégional. Etude retrospective de 138 cas. Bull Cancer. 1988;75(10):971-978.

   Not in our library

2. 2.

   Decker D. A., Drelichman A., Jacobs J., Hoschner J., Kinzie J., Loh J. J., Weaver A., Al-Sarraf M. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck. Cancer. 1983;51(8):1353-1355.

   Not in our library10.1002/1097-0142(19830415)51:8<1353::aid-cncr2820510805>3.0.co;2-i

3. 3.

   Pignon J. P., Bourhis J., Domenge C., Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-955.

   Not in our library

4. 4.

   Rooney M., Kish J., Jacobs J., Kinzie J., Weaver A., Crissman J., Al-Sarraf M. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985;55(5):1123-1128.

   Not in our library10.1002/1097-0142(19850301)55:5<1123::aid-cncr2820550530>3.0.co;2-8

5. 5.

   Schemper M., Smith T. L. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.

   Not in our library10.1016/0197-2456(96)00075-x

Cited by papers we hold 2

• Evaluation of apoptotic effect of crocin, cisplatin, and their combination in human oral squamous cell carcinoma cell line HN5 · 2021
  Not checked
• State-of-the-art management of locally advanced head and neck cancer · 2005
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.